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A large body of evidence suggests that atherosclerosis is an inflammatory disease, in which cytokines and growth
factors play a major role in disease progression. The methanolic extracts of Sphaeranthus indicus as well as its
active ingredient, 7-hydroxy frullanoide (7-HF), are shown to suppress LPS-induced cytokine production from
mononuclear cells, and inhibit the expression of VCAM1, ICAM1 and E-selectin by TNF-α- stimulated HUVECs in a
concentration-dependent manner. We tested the hypothesis that the inhibition of cytokines and adhesion molecules
should attenuate the progression of atherosclerosis, independent of changes in the lipid profile. Studies were carried
out in two animal models: a high fat-fed LDLr-/- mouse and a high fat-fed hyperlipidemic hamster. Methanolic extract
of S. indicus was dosed to hyperlipidemic LDLr-/- at 100 and 300 mg (equivalent to 20 and 60 mg 7-HF)/kg body
weight/ day for 8 weeks, and plasma lipids as well as aortic lesion area were quantitated. Hyperlipidemic hamsters
were treated with one dose of 200 mg/kg/day. S. indicus extract treatment did not alter the lipid profile in both
animal models, but reduced aortic lesion area in LDLr-/- mice and hyperlipidemic hamsters by 22 % and 45 %,
respectively. Fenofibrate, included as a reference agent, decreased aortic lesions by 26 % in LDLr -/- mice and
84 % in hyperlipidemic hamsters, respectively, which was driven by massive reductions in proatherogenic lipoproteins.
The lipid-independent anti-atherosclerotic activity of S. indicus was associated with the reductions in the circulating
levels of MCP-1, TNF-α, and IL-6 via phosphorylation and degradation of IkB-α that prevents translocation of NF-kB in
the nucleus to induce proinflammatory cytokines. Our findings demonstrate that anti-inflammatory agents that lower
pro-inflammatory proteins inhibit the progression of atherosclerosis. The methanolic extract of S. inducus, currently
being used to treat psoriasis, offer promise to benefit individuals who have high circulating pro-inflammatory cytokines,
and predisposed to coronary artery disease.Introduction
A number of studies for the past 15 years suggest that
atherosclerosis, the main cause of coronary artery
disease (CAD), is an inflammatory disease in which
inflammation plays a key role in setting the stage as well
as causing the progression of atherosclerosis (Reviewed
in [1–4]. Immune cells are predominantly present in the
early atherosclerotic lesions, and their effector molecules* Correspondence: ajitsriva@gmail.com
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leading to acute coronary syndrome [3, 5]. Thus,
immune mechanisms interact with metabolic risk factors
to initiate, propagate, and activate lesions in the arteries.
In addition to vascular endothelial and smooth muscle
cells, blood borne inflammatory and immune cells
constitute an important part of an atheroma, which is
preceded by an accumulation of lipid-laden cells in the
subendothelium [3, 6–9]. Endothelial cells recruit
leukocytes by selectively expressing major adhesion
molecule on the surface. Examples of specific adhesion
molecules involved in initiation of atherosclerotic
plaques include vascular cell adhesion molecule-1s article distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
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and endothelial cell selectin (E-selectin) [8, 9]. The
chemoattractant cytokine, monocyte chemoattractant
protein-1 (MCP-1), interacts with the monocyte
chemokine receptor CCR2, recruiting the monocytes
to the arterial endothelium and facilitating their entry
in the subendothelial space [9, 10].
During the past one decade, inflammatory nature of
atherosclerosis has attracted basic, translational, and
clinical researchers to find scientific basis leading to a
robust link between inflammatory biomarkers and
cardiovascular disease (CVD) in outcome studies. To-
wards this end, high sensitivity c-reactive protein
(hsCRP), an acute phase reactant released during inflam-
matory processes [11, 12], has been recognized as a
powerful predictor of traditional markers of cardiovascu-
lar risk [13–15]. Basic and clinical research data suggest
that treatment with statins (3-hydroxy-3-methylglutaryl
coenzyme A reductase inhibitors) to lower low-density
lipoprotein (LDL) cholesterol levels also reduces hsCRP
[16]. Additional support for the anti-inflammatory and
immunimodulatory actions of statins came from clinical
research. Thus, the magnitude of risk reduction associ-
ated with statin therapy may exceed that expected on
the basis of the LDL-C lowering alone. Prospective
evidence provided by the JUPITER trial (Justification for
the Use of Statins in Primary Prevention: an Interven-
tion Trial Evaluating Rosuvastatin) demonstrated that
patients with normal LDL-C levels but elevated hsCRP
levels showed highly significant (-44 %) reduction in
adverse cardiovascular events [17], suggesting additional
benefit of hsCRP reduction and demonstrating an
inflammatory component in the CVD risk.
Immune-mediated inflammatory disease, including
atherosclerosis, psoriatric arthritis (PsA) [18–21], and
rheumatoid arthritis (RA) [22–26], are characterized by
common inflammatory morbidity and mortality. Chronic
activation of innate and adaptive inflammatory pathways
that provide an essential defense against “foreign”
substances ranging from bacterial products to endogen-
ous oxidized lipids, may contribute to atherosclerotic
plaque progression, destabilization, and ultimately rup-
ture with subsequent clinical sequelae such as myocar-
dial infarction or stroke [20, 27].
Recently, it was demonstrated that the extract of
Sphaeranthus indicus as well as its active ingredient, 7-
HF, a sesquiterpene lactone, inhibits the LPS-induced
release/synthesis of several pro-inflammatory mediators
such as TNF-α, IL-1β and IL-6 in freshly isolated human
peripheral blood monocytes [28]. Moreover, both of
these prevented constitutive proinflammatory cytokine
production in primary cultures of rheumatoid synovial
cells, and oral administration of 7-HF effectively sup-
pressed the clinical signs of established arthritis inDBA/1 collagen-induced arthritis model [29]. However,
the antiatherosclerotic activities of S. indicus extract and
7-HF have not been evaluated. We hypothesized that the
anti-inflammatory activities of S. indicus extract and 7-HF,
shown to cause lowering of VCAM1, ICAM1, and E-
selectin, may inhibit the progression of arterial lesion
formation. To test this hypothesis, we employed two
widely studied animal models, LDLr -/- [30] and hyper-
lipidemic hamsters [31], and evaluated antiathero-
sclerotic activities of S. indicus extract. Our results
show that the antiatherosclerotic efficacy of S. indicus
methanolic extract occurs via attenuation of proinflam-
matory cytokines and adhesion molecules, and is inde-
pendent of changes in the plasma lipid profiles.
Materials and methods
Reagents
RPMI 1640 medium, anti-β-actin, anti-histone, phena-
zine methosulfate (PMS), Dulbecco’s phosphate buff-
ered saline (DPBS) and fetal bovine serum (FBS) were
purchased from Sigma. Calpain Inhibitor I, and
antibodies against IκBα phosphorylated IκBα p65 were
obtained from Calbiochem (Merck Biosciences). Anti-
ICAM-1 (clone BBIG-I1) anti-VCAM-1 (clone BBIG-V1)
and anti-E-selectin (clone BBIG-E4), isotype control
mouse IgG1 (clone 11711.11), the secondary antibody
(anti-mouse IgG-HRP antibody) and bacteria derived
recombinant human TNF-α were products of R&D
Systems (Minneapolis, MN). Protease inhibitor cocktail
was procured from Roche. The CellTiter 96® Aqueous
One Solution Cell Proliferation Assay were purchased
from Promega (Madison, WI).
Source of Sphaeranthus Indicus and 7-hydroxy frullanolide
Methanolic extract of the fruits of Sphaeranthus Indicus
was prepared in-house and dissolved in DMSO as a
20 mg/ml stock as described [28]. 7-hydroxy frullano-
lide (7 HF), isolated in-house from the above plant was
dissolved in DMSO as a 20 mM stock. It was purified
and identified with the use of ESI-MS and 1H- and
13C-NMR analyses [28].
Human peripheral blood mononuclear cells assay
Human peripheral blood mononuclear cells (PBMC) were
harvested using Ficoll- Hypaque density gradient centrifu-
gation (1.077 g/ml; Sigma Aldrich; St. Louis, MO) from
healthy volunteers and suspended in assay medium [RPMI
1640 culture medium (Sigma Aldrich) containing 10 %
heat inactivated fetal bovine serum (FBS; JRH Biosciences;
Lenexa, KA), 100U/ml penicillin (Sigma Aldrich) and
100 μg/ml streptomycin (Sigma Aldrich)]. PBMC (2 × 105)
per well were transferred into a 96-well plate. The cells
were pre-treated with varying concentrations of 7HF, S.
indicus extract, or 0.5 % dimethyl sulfoxide (DMSO) or
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5-(4-pyridyl) imidazole [SB203580; a p38 MAPK inhibi-
tor which is known to suppress induced production of
TNF-α and IL-6; Sigma Aldrich] for 1 h at 37 °C, 5 %
CO2 and stimulated with 1 μg/ml lipopolysaccharide
(LPS; Escherichia coli serotype 0127:B8; Sigma Aldrich).
The cells were incubated for 6 h at 37 °C, 5 % CO2
followed with collection of supernatants and assayed for
TNF-α, IL-6, IL-8, and IL-1β by Enzyme-Linked
Immunosorbent Assay (ELISA; OptiEIA ELISA sets; BD
Biosciences). The 50 % inhibitory concentration (IC50)
values were calculated by a nonlinear regression method
using GraphPad software (Prism 3.03). In all experi-
ments, a parallel plate was run to ascertain the toxicity
of 7HF. The toxicity was determined using the CellTiter
96® AQueous One Solution Cell Proliferation Assay (Pro-
mega; Madison, WI). In every experiment, each condition
was run in triplicate wells.
Endothelial cell culture
Human umbilical vein endothelial cells (HUVECs) and
the complete medium were obtained from Cascade
Biologics (Portland, Oregon). Cells were grown in endo-
thelial cell growth medium M200 supplemented with
2 % low serum growth supplements as per the manufac-
turer’s recommended protocol. The growth medium was
changed every other day until confluence. Cells under
passage 8 were used for this study. The cells used for the
experiments had a viability >98 % as determined by
trypan blue exclusion test.
Evaluation for the viability of endothelial cells
The CellTiter 96® Aqueous One Solution Cell Prolifera-
tion Assay (Promega) was used to assess cell viability.
The assay is composed of the tetrazolium compound
MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxy-
phenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt) and
an electron coupling reagent (PMS). The soluble
product in the medium was measured with a spectro-
photometer at 490-nm absorbance. Background ab-
sorbance from the control wells (same media, no cells)
was subtracted. Cells incubated in control media were
considered 100 % viable.
Cell enzyme-linked immunosorbent assay
The surface expression of endothelial cell adhesion
molecules was quantified using cell enzyme-linked
immunosorbent assay. Briefly, confluent HUVECs in 96-
well fibronectin–coated plates were pretreated with
various concentrations of S. indicus or 7-HF for 30 min
before being stimulated with 1 ng/mL TNF-α for the
indicated time. The expressions of ICAM-1 and E-
selectin were evaluated after TNF-α stimulation for 4 h,
and expression of VCAM-1 was evaluated after 6 h ofstimulation. The cells were fixed with 1 % paraformalde-
hyde and the non-specific binding of antibody was
blocked using bovine serum albumin (2 % in DPBS). The
cells were then washed and incubated with monoclonal
mouse anti-human ICAM-1, VCAM-1, E-selectin or the
isotype control mouse IgG1 overnight at 4 °C. Subse-
quently, cells were washed and incubated with a horse-
radish peroxidase-conjugated goat anti-mouse IgG for
90 min. Binding of the secondary antibody was deter-
mined by incubating with 3,3′,5,5′ tetramethylbenzidine
(TMB) substrate from BD Biosciences (SD California)
and then terminating the reaction by 2 N sulphuric acid.
Surface expression of adhesion molecules was quanti-
fied by measuring absorbance at 490 nm in an auto-
mated microtitre plate reader (Spectramax, Molecular
Devices, USA).IkBα phosphorylation
To assay IκBα, cytoplasmic extracts were prepared from
cells pretreated with either S. indicus extract or 7 HF for
2 h and then stimulated with TNF-α either in the
presence or absence of ALLN, a calpain inhibitor,
resolved on 10 % sodium dodecyl sulfate-polyacrylamide
gels. After electrophoresis, the proteins were transferred
to nitrocellulose membrane, probed with antibodies
against either IκBα or phosphorylated IκBα at serine 32,
and detected by chemiluminescence (ECL; Sigma).NF-κB protein localization
For the determination of NF-κB localization, Western
blot analysis was carried out with cytoplasmic and
nuclear extracts using anti-human NF-κB primary anti-
body. These extracts were prepared as per manufac-
turers protocol (Chemicon). Briefly, treated cells were
lysed in 300 μl of hypotonic lysis buffer containing
10 mM HEPES (pH 7.9), 1.5 mM MgCl2, 10 mM KCl,
0.5-5 mM DTT, 0.1 % Triton X-100, sodium orthovana-
date, 1 mM and protease inhibitor cocktail. The residual
pellet after cytosolic fraction collection was treated with
extraction buffer containing 20 mM HEPES (pH7.9),
1.5 mM MgCl2, 0.42 M NaCl, 0.2 mM EDTA, 0.5-5 mM
DTT, 1.0 % NP-40, 25 % (v/v) glycerol, sodium orthova-
nadate, 1 mM, and protease inhibitor cocktail. Twenty
microgram protein were taken for Western Blot analysis
as described above.In vivo cytokine production study
Group of 10 mice were treated orally with Sphaeranthus
Indicus methanolic extract, 60 min prior to lipopolysac-
charide injection (1 mg/kg, i.p.). Levels of TNF-α in the
plasma, were measured 1.5 h after lipopolysacchride
injection, and IL-1β were done 4 b after LPS treatment.
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Quantitation of messenger RNA (mRNA) was done in
aortic total RNA by real-time quantitative RT-PCR using
an ABI Prism 7700 sequence detector. All PCR reactions
were performed in a total volume of 50 μl and included
the following components: cDNA derived from 20 ng of
total RNA, 400 nM each of forward and reverse primers,
RNase-free water, and 25 μl of Power SYBR Green PCR
Master Mix (ABI), an optimized buffer system contain-
ing AmpliTaq Gold DNA polymerase and dNTPs. All
PCR reactions were performed in quadruplicate using
pooled cDNA samples (n = 6). Cycling parameters were
as follows: after an initial denaturation step for 10 min
at 95 °C, 40 subsequent cycles were performed in which
samples were denatured for 15 s at 95 °C followed by
primer annealing and elongation at 60 °C for 1 min.
Relative quantities of mRNA were calculated from CT
values using the comparative CT method (ΔΔCT; [32]
using GAPDH as an internal reference. Primer pairs
for real-time PCR were designed using Primer3
software and sequence information obtained from
GenBank (NCBI).
Atherosclerosis intervention study in hamsters
Animals and diet
All animal procedures were performed as per guidelines
provided by the Institutional Animal Care and Use
Committee. Golden Syrian (GS) hamsters (10-12 weeks
old) obtained from Charles River, were housed in groups
of three in appropriately sized solid-bottom cages with
contact bedding. Room lighting conditions were adjusted
to 12 h light and 12 h dark cycle as follows: light
between the hours of 6 AM to 6 PM and dark between
the hours of 6 PM to 6 AM. All animals were allowed to
acclimate for 5 days in the vivarium and were fed stand-
ard rodent chow unless otherwise mentioned before
initiating the study.Study details
After the acclimation period, baseline blood chemistry
was done in animals after 12-h fasting followed by blood
(700 μl – 800 μl) withdrawal by retro-orbital puncture in
a 3 ml Vacutainer® tube containing K3EDTA. Blood sam-
ples were centrifuged (4000 rpm, 20 min, 4 °C) in an
Eppendorf tube to obtain plasma, which was transferred
(250–300 μl) into a clean tube. The aliquot of plasma
sample was analyzed for triglycerides, total cholesterol,
LDL-C, direct-HDL-C, glucose, AST and ALT. LDL,
triglycerides, cholesterol, and glucose were quantitated
on automated chemistry analyzer, Hitachi 917, using
Roche diagnostic kits (Indianapolis). After bleeding, ani-
mals were earmarked for identification and then were
returned to their cages and feed replaced. All animalswere put on a high fat diet consisting of Purina 5001
plus 10 % coconut oil, 10 % corn oil, 0.5 % cholesterol,
and 5 % fructose. This diet composition accelerates
hyperlipidemia in hamsters. Animals were fed high fat
diet for 4 weeks. This study started with a total of 50
animals. At the end of 4 weeks of feeding high fat high
cholesterol diet, the hamsters were fasted overnight and
bled as described above. Plasma samples were analyzed
for total cholesterol, triglycerides, LDL-C, HDL-C,
glucose, AST and ALT as described above. Based on the
body weight, and blood chemistry those animals that
did not develop adequate hyperlipidemia (total choles-
terol >1000 mg/dl and total triglycerides >1200 mg/dl)
were excluded from the study before grouping [33].
Animals were then randomly grouped into 3 groups of
10 animals in each group as follows: group 1- vehicle con-
trol CMC 0.5 %; group 2- fenofibrate 100 mg/kg/day;
group 3- methanolic extract of S. indicus 200 mg/kg/day.
Animals were fed high fat high cholesterol diet and
concomitantly dosed by oral gavage once daily in the
morning between 8 and 9 AM. At the end of 10 weeks of
treatment, hamsters were euthanized under CO2 and
blood withdrawn by cardiac puncture and processed as
described above. The thorax was opened and vasculature
perfused first with heparinized saline (40 units/ml) for
2 min and then with 10 % formalin for 5 min. The aorta
attached to heart and containing aortic arch, thoracic and
abdominal aorta to the femoral artery bifurcation were re-
moved and placed in 10 % formalin for en face stain-
ing and lesion quantitation. Aortic lipid contents were
quantitated by en face staining with Oil Red O and
atherosclerotic lesion area coverage determined by
image analysis.
Isolated aortae from the above study were placed
on to a tray containing black wax. Connective tissues
sticking around the artery were removed as much as
possible. Abdominal aorta and renal arteries, iliac
bifurcation, aortic arch and major branches were ex-
posed. The aorta was snipped at the heart where it
leaves the heart. Major branches were snipped at
approximately 0.5 cm away from where it joins the
aorta. Iliac arteries were snipped from the bifurcation
point. The aorta was placed into 10 % formalin for
lesion measurement.
Each section of the aorta was opened longitudinally
and pinned to a black wax plate using stainless steel
pins. The plate containing the aorta sections was then
rinsed with 70 % ethanol (5 min), immersed in Oil Red
O staining solution (10 min) followed by destaining
with 70 % ethanol on a shaker for 5 min at room
temperature. The aorta was rinsed with deionized water
and then submerged with PBS. Quantitation and
imaging was done as described [33]. Atherosclerosis
burden was expressed as % lesion per area.
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Animals and diet
Male LDLr-/- mice (C57Bl/6 J background) were pro-
cured from Jackson Laboratories (Bar Harbor, Maine) at
6 weeks of age. Mice were allowed to acclimatize on
regular chow diet for one week followed by feeding a
high fat high cholesterol (HF) diet with 45 % calories
from butter fat plus 0.21 % cholesterol for 2 weeks to
acclimatize to the high fat diet. On an average, the food
consumption was around 3 g/day. One group of mice
was fed rodent chow, Purina 5001 (n = 11).Fig. 1 Sphaeranthus Indicus extract inhibits lipopolysaccharide-Study details
After the acclimation period of one week, baseline
blood chemistry was done in animals after 4-h fasting
followed by blood (150 μl) withdrawal by retro-orbital
puncture tube containing K3EDTA. Each blood sample
was centrifuged (4000 rpm, 20 min, 4 °C) using an
Eppendorf tube, and the supernatant transferred into a
new clean tube. The aliquot of plasma sample was
analyzed for triglycerides and total cholesterol. After
bleeding, animals were earmarked for identification and
then were returned to their cages and feed replaced. All
animals were put on a high fat diet consisting of Purina
5001 plus 21 % fat, and 0.21 % cholesterol.
The LDLr -/- mice on high fat diet were divided into 3
groups (n = 11/group) as follows: Group 1- Vehicle, high
fat high cholesterol (HF) with 45 % calorie from butter
milk and 0.21 % cholesterol; Group 2, HF diet plus
Methanolic extract of S. indicus (100 mg/kg body
weight/day); Group 3, HF diet plus methanolic extract of
S. indicus (300 mg/kg body weight/day). Mice were fed
pelleted HF diet, and test agent was administered by oral
gavage in the morning once daily. New batches of dosing
solution was prepared every week and stored as aliquots
at 4 oC. Food was replaced with fresh food at the inter-
vals of every 3 days. Body weights were monitored every
week, and feeding continued for 8 weeks. At the end of
8 weeks of treatment, mice were bled retro-orbitally
under isoflurane anesthesia, and plasma analyzed for
triglycerides, cholesterol, LDL-C, HDL-C, glucose, and
cytokine level. Mice were sacrificed by carbon dioxide
asphyxiation. Aorta were removed, and processed for
Oil Red O staining as described [34, 35]. Aortae from 4
mice in each group were isolated without formalin
fixing to prepare total RNA [30].induced TNF-α production in human peripheral monocytic cells.
Freshly isolated human peripheral blood monocytes were pretreated
with S. indicus extract ranging in concentration from 0.01 to 100 μg/ml for
30 min followed by treatment with LPS and incubation for 6 h at 37 °C,
5 % CO2 followed with collection of supernatants and measurements for
TNF-α, IL-6, IL-8, and IL-1β by ELISA Assay. The 50 % inhibitory
concentration (IC50) values were calculated by a nonlinear regression
method using GraphPad softwareStatistical analysis
Mean values of treated groups were compared to those
of the vehicle treated group. Statistical significance
was determined by ANOVA. Statistical comparisons
across treatment groups were done. All results werepresented as mean ± SD. A p value of <0.05 was con-
sidered significant.Results
S. indicus extract decreases TNF-α stimulated
pro-inflammatory cytokines in human peripheral blood
monocytic cells
Screening of natural products for their anti-inflammatory
activities were performed in monocytes isolated from
human peripheral blood. To induce cytokine production,
PBMC was stimulated with LPS and inhibition of cytokine
secretion was measured. As shown in Fig. 1, S. indicus ex-
tract inhibited pro-inflammatory cytokines, TNF-α, IL1-β,
IL-6, and IL-8. The concentration needed to achieve
maximal inhibition for each cytokines was found to be
different. Whereas significant inhibition in the secretion
of IL1-β was seen at as low as 1 μg/ml concentration, it
required 3 and 10 μg/ml S. indicus extract to have similar
inhibition for TNF-α and IL-6 production. While
30 μg/ml S. indicus extract resulted in >80 % inhibition
in TNF-α, IL1-β and IL-6 production, inhibition of IL-8
secretion was ~70 %. The IC50 for TNF-α, IL1-β, IL-6,
and IL-8 were 3.5, 2.1, 10, and 25 μg/ml, respectively.
The maximal efficacious concentration showed no
toxicity in this study.
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of VCAM-1, ICAM-1 and E-selectin by TNF-α
stimulated HUVECs
As cell adhesion molecules play an important role
during inflammation, we analysed the effect of different
concentrations of S. indicus extract and 7-HF on TNF-
α-induced cell surface expression of these molecules. In
accordance with previous studies, ICAM-1 and E-
Selectin were expressed at low levels in unstimulated
HUVECs, but their expression was increased after
TNF-α stimulation (data not shown). High-dosage
(10 μg/ml) but not low-dosage (3 μg/ml) S. indicus ex-
tract significantly inhibited TNF-α induced ICAM-1
(54 ± 14 %), VCAM-1 (64 ± 9 %) and E-selectin (88 ±
8 %), respectively (Fig. 2). The IC50 values of S. indicus
extract to ICAM-1, VCAM-1 and E-selectin expressio
were 11.43, 6.43, and 4.61 μg/ml, respectively. 7-HF, at
a concentration of 1 and 3 μM also significantly re-
duced the expression of ICAM-1 (52 ± 16 % and 75 ±
17 %), VCAM-1 (76 ± 3 % and 90 ± 7 %) and E-selectin
(96 ± 2 % and 100 ± 0 %) respectively. The IC50 values
of 7-HF to ICAM-1, VCAM-1 and E-selectin were 0.73,Fig. 2 Sphaeranthus Indicus extract inhibits TNF-α-induced production of a
HUVECs in 96-well fibronectin–coated plates were pretreated with various
with 1 ng/mL TNF-α for the indicated time. The expressions of ICAM-1 and E-
VCAM-1 was evaluated after 6 h of stimulation. The 50 % inhibitory concentra
GraphPad software0.39, and 0.29 μM, respectively. Taken together, these
findings indicate that S. indicus extract as well as its
active ingredient, 7-HF specifically inhibit cytokine-
induced expression of adhesion molecules in a dose-
dependent manner.
The cell cytotoxicity was assessed by MTS assay.
Treatment of HUVECs with 1 ng/mL of TNF-α did
not result in cytotoxicity (data not shown). When in-
cubated with 1, 3 and 10 μg/mL of S. indicus extract,
cell viability was 89 ± 3 %, 89 ± 3 % and 100 ± 0 % re-
spectively. Treatment with 0.3, 1 and 3 μM did not
affect cell viability (89 ± 3 %, 89 ± 3 % and 100 ± 0 %
respectively).
Effect of S. indicus extract on inhibition of TNF-α and
IL-1β production in mice
Groups of 10 mice were treated orally with Sphaeranthus
Indicus methanolic extract, 60 min prior to lipopolysac-
charide injection (1 mg/kg, i.p.). Levels of TNF-α in the
plasma were measured 1.5 h after lipopolysaccharide
injection, and IL-1β were done 4 h after LPS treatment.
The results shown in Fig. 3a suggest a dose-dependentdhesion molecules human umbilical vein endothelial cells. Confluent
concentrations of S. indicus or 7-HF for 30 min before being stimulated
selectin were evaluated after TNF-α stimulation for 4 h, and expression of
tion (IC50) values were calculated by a nonlinear regression method using
Fig. 3 a Sphaeranthus Indicus extract inhibits lipopolysaccharide-induced TNF-α production in mice. Groups of 10 mice were treated orally with
Sphaeranthus Indicus methanolic extract, 60 min prior to lipopolysaccharide injection (1 mg/kg, i.p.). Levels of TNF-α in the plasma were measured
1.5 h after lipopolysaccharide injection. Results are expressed as the mean ± S.E.M. *P < 0.001 significantly different from LPS control (students
t test). b Sphaeranthus indicus extract inhibits lipopolysaccharide-induced IL-1β production in mice. Groups of 10 mice were treated orally with
S. indicus 60 min prior to lipopolysaccharide injection (2 mg/kg, i.p.). Amounts of IL-1β in the plasma were measured 4 h after lipopolysaccharide injection.
Results are expressed as the mean ± S.E.M. *P< 0.001 significantly different from LPS control (students t test)
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S. indicus extract showing maximal inhibition (~80 %).
Rolipram, used as a reference agent, showed robust
inhibition of LPS-induced TNF-α production. The
effect of S. indicus extract on IL-1β was found to be
even more robust (Fig. 3b), showing >60 % inhibition at
30 mg/ml concentration, which was as effective as
rolipram. Heat inactivated and denatured extract
(400 mg/kg dose) did not show any efficacy.
Effect of S. indicus extract and 7-HF on NF-κB activation
by TNF-α
The TNF-α induced expression of adhesion molecules
ICAM-1, VCAM-1 and E-selectin requires the transcrip-
tion factor NF-κB [36, 37]. NF-κB is also involved in the
inflammatory diseases like arthritis [38] and psoriasis
[39]. Therefore, we studied the effect of S. indicus
extract and 7-HF on the nuclear translocation of the
NF-κB p65. We carried out Western blot analysis to de-
termine the levels of NF-κB p65 in the cytoplasmic and
nuclear extracts from HUVEC treated with TNF-α in the
presence or absence of S. indicus extract and 7-HF. As
shown in Fig. 4a & b, TNF-α induced nuclear transloca-
tion of NF-κB p65 occurs within 15 min (Lane 4). In
contrast, S. indicus extract and 7-HF, at a concentration
of 15 μg/ml and 3 μM respectively, decreased the
amount of nuclear NF-κB, with a concurrent increase in
the amount of cytoplasmic NF-κB (Fig. 4a). Thus, S.
indicus extract and 7-HF completely abolished nuclear
translocation of NF-κB p65. Although equal amount of
protein was taken for Western blotting, which wasdetermined by a linear curve obtained from amount of
protein loaded and the respective protein band inten-
sity, these results should be interpreted cautiously.
Effect of S. indicus extract and 7-HF on TNF-α-induced
phosphorylation and degradation of IκBα
TNF-α-induced regulation of NF-κB involves the phos-
phorylation, ubiquitination and degradation of the cyto-
plasmic inhibitor, IκB-α [40]. To determine whether S.
indicus extract and 7-HF inhibits NF-κB activation due
to an effect on the phosphorylation and/or degradation
of IκBα, the cytoplasmic IκBα protein levels were exam-
ined by Western blot analysis. The results show that a
37-kDa protein was detected in the cytoplasmic extract
of untreated cells at time 0 min (Fig. 5a, lane 1) whereas
TNF-α treatment caused a loss of IκB-α after 15 min
(Fig. 5a, lane 3). Thereafter, IκB-α was reactivated
60 min onwards (Fig. 5a, lane 5 and 6), possibly by NF-
κB, as NF-κB is known to bind and activate the IκB-α
promoter. The pretreatment of cells with S. indicus ex-
tract at 15 μg/ml completely abolished TNF-α-induced
degradation of IκB-α (Fig. 5a, lane 3 and 4), but 7-HF
did not show similar results (Fig. 5a, lane 3 and 4). In
fact, IκB-α was not resynthesized even after 60 min in
presence of 7-HF (Fig. 5a, lane 5 and 6). This is not
surprising since inhibition of NF-κB activity would also
inhibit the regeneration of IκB-α mRNA.
To ascertain whether S. indicus extract inhibits IκB-α
degradation by blocking its phosphorylation, the
cyoplasmic extracts were examined by western blot ana-
lysis using antibodies that detect only the serine-
Fig. 4 Effect of S. indicus extract and 7 HF on the nuclear translocation of NF-kB p65 in TNF-α-stimulated HUVECs. Briefly, confluent HUVEC
monolayers were pretreated with 15 μg/mL S. indicus extract or 3 μM 7 HF for 1 h followed by stimulation with 0.1nM TNF-α for the time
points. The cytosolic (Panel a) as well as nuclear (Panel b) extracts were prepared (as described in materials and methods) and analyzed by
Western blot analysis with a primary antibody against human NF-kB p65 (3 independent experiments). Upper row shows treatment with TNF-α, middle
rows shows treatment with TNF-α + S. indicus extract, and lower row shows TNF-α + 7-HF
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the serine phosphorylated form of IκBα appears at 15
and 30 min (Fig. 5b, lanes 3 and 4), which completely
disappeared when cells were pretreated with S. indicus
extract (Fig. 5b, lanes 3 and 4), indicating that it com-
pletely abolished the TNF-α induced phosphorylation
of IκB-α. However, the cells pretreated with 7-HF did
not show similar results. While the differences in the
untreated and treated groups are evident when equal
amounts of protein was loaded to each lane, it shouldFig. 5 Effect of S. indicus extract and 7 HF on TNF-α-induced phosphorylat
pretreated with 15 μg/mL S. indicus extract or 3 μM 7 HF for 1 h followed
extracts were prepared (as described in materials and methods) and then
human IkB-α (a) phosphorylated IkB-α Κ (b) (3 independent experiments)be noted that internal control was not included. Never-
theless, the results do indicate inhibition of IκBα
phosphorylation.
Taken together, the cell ELISA and Western blot
analysis, suggest that S. indicus extract inhibits TNF-
α-induced IκBα phosphorylation and degradation,
which causes a decrease in NF-κB resulting in decreased
surface expression of adhesion molecules. In contrast,
7-HF, one of its bioactive principles, without affecting
the phosphorylation and degradation of IκB-α, inhibitsion and degradation of IkB-α. Briefly confluent HUVEC monolayers were
by stimulation with 0.1 nM TNF-α for the time points. The cytosolic
analyzed by Western blot analysis with a primary antibody against
Fig. 6 Effect of S. indicus on body weight in diet-induced hyperlipidemic hamsters. Body weight measurements were carried out 18 times at the
interval of 3 days during the course of 60 days study
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expression of adhesion molecules.
Effect of S. sphaericus extract on plasma lipids and
atherosclerosis in hamsters
Feeding high fat high cholesterol diet caused gradual in-
crease in body weight (Fig. 6), showing a 30 % increaseFig. 7 Effect of S. indicus extract on circulating lipids in diet-induced hyper
8 weeks and concurrently treated with S. indicus preparation. At the end of
Panel a, Cholesterol; Panel b, Triglycerides; Panel c, LDL; Panel d, HDLafter 59 days. The treatment group showed no difference
in body weight gain on high fat high cholesterol diet
during the same period, suggesting that there was no
adverse effect of the S. indicus extract treatment up to
200 mg/kg body weight/day in hyperlipidemic hamsters.
The total cholesterol and triglycerides rose to 1700 mg/dl
and 2200 mg/dl, respectively (Fig. 7). The hamster modellipidemic hamsters. Hamsters were fed on hyperlipidemic diet for
8 weeks of treatment blood were withdrawn for lipid analyses.
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total cholesterol and LDL-C remained unchanged in
the S. indicus extract treated group, however, there was
a small change in triglyceride level. Fenofibrate, known
to lower lipids in the hyperlipidemic hamsters [31, 33],
showed similar hypolipidemic effect with massive re-
ductions in total cholesterol, triglycerides and LDL-C
(Fig. 7a-d). Since insulin resistance and diabetes may
also influence arterial lipid deposition [41], we mea-
sured plasma levels of glucose shown in Fig. 8. There
was a modest decrease in the glucose levels in S. indicus
extract treated as well as fenofibrate treated groups.
In the control vehicle treated hamsters, 0.5 % of the
aorta was found to have lesions (Fig. 9). Fenofibrate,
included as a reference agent, reduced lesion area by
more than 80 %. This reduction in lesion area was
associated with massive reductions in proatherogenic
lipoproteins. Treatment with S. indicus extract reduced
aortic lesion by more than 40 % without changes in the
proatherogenic lipoproteins.
Effect of S. sphaericus extract on plasma lipids and
atherosclerosis in LDLr-/- mice
Anti-atherosclerotic and anti-hyperlipidemic activities of
S. indicus extract were also evaluated in a mouse model
of atherosclerosis at two concentrations, 100 and
300 mg/kg/d. While there was no change in body weight
at 100 mg/kg/d dose (Fig. 10), a non-significant increase
in body weight was noticed at 300 mg/kg/d dose,
suggesting that this high dose was safe in animal model
of atherosclerosis. As expected [30], fenofibrate pre-
vented body weight gain. Feeding high fat high choles-
terol diet raised total cholesterol and triglycerides ~1200
and ~600 mg/dl, respectively (Fig. 11). While fenofibrate
decreased proatherogenic lipoproteins and triglycerides,
S. indicus preparation did not change circulating lipo-
proteins and triglycerides (Fig. 11). Since a high dose of
S. indicus preparation was used in this study, we also
measured some of the parameters indicative of safety. As
shown in Fig. 12, no significant changes were observed
in AST and ALT levels.Fig. 8 Effect of S. indicus extract on plasma glucose in diet-induced
hyperlipidemic hamstersHigh fat and cholesterol feeding to LDLr-/- mice
caused almost 4 % coverage of aorta with lipids as mea-
sured by neutral lipid staining. Treatment with fenofi-
brate showed a reduction of 26 % in lipid staining. S.
indicus preparation reduced lesion area by 22 % at
100 mg/kg/day dose. Increasing the dose of S. indicus
preparation did not show any advantage either in terms
of overall lipid profile or the extent of reductions in
lesion area (Fig. 13).
Effect of S. sphaericus extract on cytokines in LDLr-/- mice
To evaluate anti-inflammatory efficacy in atherosclerosis
model, we measured circulating pro-inflammatory cyto-
kines and adhesion molecules to ascertain its role in
anti-atherosclerotic properties. Since IL-6 is a pro-
inflammatory cytokine [42] and MCP-1, a cell adhesion
molecule and a proatherogenic marker [43], we mea-
sured these two proteins in the serum. As shown in
Fig. 14, there was 4-fold increase in the levels of MCP-1
as a result of high fat and cholesterol feeding, which
decreased more than 2-fold following treatment with
100 mg/kg/day of S. indicus preparation. High fat high
cholesterol diet caused only modest increases in IL-6
levels, however, treatment with S. indicus preparation
caused significant reduction (~50 %) at 100 mg/kg/day
dose and 75 % reduction at 300 mg/kg/day dose. To
assess if the changes in MCP-1 occurred as a result of
transcriptional activation, RNA from aorta was prepared
and MCP-1 mRNA quantitated. There was a 2.5-fold
increase in the aortic MCP-1 mRNA in the vehicle
treated group when compared to MCP-1 level at the
start of the high fat feeding, which decreased by 40 %
following treatment with S. indicus preparation (Fig. 15).
Fenofibrate treatment also showed similar reductions in
MCP-1. Since the levels of TNF-α could not be reliably
measured in the plasma because of low levels, we
attempted to measure TNF-α mRNA in the RNA
prepared from aorta. The results of TNF-α measure-
ments shown in Fig. 15 suggest that high fat feeding
does increase TNF-α mRNA in the aorta by ~3-fold.
Treatment of high fat-fed LDLr-/- mice with S. indicus
preparation caused a ~30 % reduction in TNF-α mRNA.
Both IL-6 and IL1-β did not show significant changes
(data not shown).
Discussion
In the course of screening natural products to find
novel anti-inflammatory drugs as TNF-α inhibitors we
found that S. indicus extract and 7-HF, one of its
active constituents, characterized as a sesquiterpene
lactone, suppresses the cytokine production in a
concentration-dependent manner from LPS-stimulated
human peripheral blood mononuclear cells as well as from
synovial cells obtained from rheumatoid arthritis patients
Fig. 9 Effect of S. indicus extract on aortic lipid deposition in diet-induced hyperlipidemic hamsters. Animals were fed high fat high cholesterol
diet and concomitantly dosed by oral gavage At the end of 10 weeks of treatment, hamsters were euthanized under CO2 and blood withdrawn
by cardiac puncture and processed plasma lipid and glucose analysis. Their thorax was opened and vasculature perfused first with heparinized
saline then with 10 % formalin. The aorta attached to heart and containing aortic arch, thoracic and abdominal aorta to the femoral artery bifurcation
were removed and placed in 10 % formalin for en face staining and lesion quantitation. Aortic lipid contents were quantitated by en face staining with
Oil Red O and atherosclerotic lesion area coverage determined by image analysis
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antly, S. indicus extract was also found to arrest
disease progression in an in vivo mouse model for
rheumatoid arthritis [29]. Since atherosclerosis is an
inflammatory disease [44], we sought to investigate if
anti-inflammatory activities of S. indicus inhibited
atherosclerosis progression. We also looked into the
mechanism of anti-inflammatory properties of S. indicus.
It has been previously documented that sesquiterpene
lactones or sesquiterpene lactone-containing plant
extracts exert potent anti-inflammatory effect, at least in
part, through inhibition of transcription factor NF-κB
[45], causing a decrease in adhesion molecule expressionFig. 10 Effect of S. indicus on body weight in diet-induced hyperlipidemic
out at the interval of 3 days during the course of studyand subsequent leukocyte adhesion. Here, we show that
natural product, S. indicus extract along with one of its
active constituent, 7-HF mediate anti-inflammatory
effects by effectively modulating the expression of cell
adhesion molecules via suppression of NF-κB/IκBα
signaling in TNF-α activated HUVECs.
Clearly, S. indicus extract (at the dose of 10 μg/ml) sig-
nificantly inhibited the expression of the ICAM-1 (54 %
inhibition), VCAM-1 (64 % inhibition), and E-selectin
(88 % inhibition) in TNF-α activated HUVECs (Fig. 2).
Likewise, 7-HF, a sesquiterpene lactone, (at the dose of
3 μM) dramatically inhibited ICAM-1 (75 % inhibition),
VCAM-1 (90 % inhibition), and E-selectin (100 %LDL receptor-deficient mice. Body weight measurements were carried
Fig. 11 Effect of S. indicus extract on circulating lipids in diet-induced hyperlipidemic LDL receptor-deficient mice. Mice were fed Western Diet for
4 weeks followed by treatment with S. indicus preparation by oral gavage for 8 weeks. Mice were fed WD during treatment period. At the end of
8 weeks of treatment, mice were bled retro-orbitally under isoflurane anesthesia, and plasma analyzed for triglycerides, cholesterol, LDL-C, and
HDL-C
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effects with compounds such as 1,4-Dihyroxyxanthone
(65 μg/mL) [46], diclofenac (750 μM) [47], pyrrolidine
dithiocarbamate (1 mM) [48] and N-acetyl cysteine
(100 μM) [49] on cytokine-induced expression of cell
adhesion molecules have been demonstrated by
previous investigators, albeit at higher concentrations.
Interestingly, S. indicus extract and one of its bioactive
components, 7-HF, were found to be effective at com-
paratively lower concentrations and therefore, may be
used in controlling various pathological conditions
associated with upregulation of endothelial leukocyte
adhesion molecules such as atherosclerosis, bacterial
sepsis, inflammation and tumor metastasis.
To further delineate the mechanism by which S.
indicus extract and 7-HF may be acting, we studied its
effect on NF-κB activation. Using Western blot analysis,
we show that S. indicus extract and 7-HF both appear to
block TNF-α induced p65 translocation from the cyto-
plasm to the nucleus. In this respect, 7-HF possibly
behaves differently from other known sesquiterpene
lactones [45] such as helenalin [50], parthenolide [51]
and isodeoxyelephantopin [52], which exert their anti-
inflammatory effect by either targeting the IκB kinase
complex or inhibiting the DNA binding of p65homodimer. The mode of action of 7-HF appears to
be similar to compounds like caffeic acid phenethyl
ester (CAPE) [53] and DHMEQ [54], which block
NFκB by inhibiting its binding to promoter DNA with-
out affecting the degradation of IκB-α. Because NF-κB
is responsible for the induced expression of ICAM-1,
VCAM-1 and E-selectin [55], these results suggest that
both these agents inhibit NF-κB dependent transcrip-
tion of cell adhesion molecule genes. However, it is
quite possible that S. indicus extract and 7 HF may also
inhibit other transcription factors.
In addition, we also showed that pretreatment of cells
with proteasome inhibitor ALLN prevents the destruc-
tion of IκB-α and results in accumulation of phosphory-
lated IκB-α. On the other hand, treatment of cells with
S. indicus extract did not result in the accumulation of
phosphorylated IκB-α in the cytoplasm. This led us to
conclude that S. indicus extract possibly prevents NF-κB
by preventing phosphorylation of IκB-α rather than
proteolysis per se [40]. It is well known that the pathway
leading to activation of NF-κB is common for these
activators, implying that S. indicus extract acts at a
molecular step common to both the LPS- and TNF
pathways, which could be at the level of IKK or upstream
of IKK. The effect of S. indicus extract on the cascade
Fig. 12 Effect of S. indicus extract on plasma glucose and markers of
liver toxicity in diet-induced hyperlipidemic LDL receptor-deficient
mice. Panel a, Glucose; Panel b, AST; Panel c, ALT
Fig. 13 Effect of S. indicus extract on aortic lipid deposition in diet-induced
Diet for 4 weeks followed by treatment with S. indicus preparation by oral
the end of 8 weeks of treatment, mice were bled retro-orbitally under isofl
removed and processed for Oil Red O staining
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quite possible that S. indicus extract may suppress
different steps in the NF-κB activation pathway.
The standardized S. indicus extract (10 μg/ml) con-
tains approximately 0.6 μg/ml or 3 μM of 7-HF, and
since we observed similar effects of S. indicus extract at
10 μg/ml and 7-HF at 3 μM (data not shown), we postu-
lated that the effects on the expression of cell adhesion
molecules and NF-κB activation seen with the crude
extract of S. indicus extract may be related to its content
of 7-HF. However, there are as yet uncharacterized
active components besides 7-HF, which may be respon-
sible for the additional potency of S. indicus extract that
is reflected in the inhibition of IκB-α phosphorylation
and degradation.
Thus, S. indicus extract and 7-HF a) significantly
reduced ICAM-1, VCAM-1 and E-selectin expression;
b) markedly inhibits the translocation of p65 from
cytoplasm to the nucleus; and c) inhibits IκB-α phos-
phorylation and degradation. These activities of S.
indicus extract and 7-HF suggest its potential to treat
a wide variety of NF-κB-linked pro-inflammatory
diseases such as rheumatoid arthritis, atherosclerosis
and inflammatory bowel disease.
We, therefore, evaluated anti-atherosclerotic activities
of S. indicus preparation in two widely studied animal
models of atherosclerosis. Based on our in vitro results,
we chose a dose equivalent to 120 mg/kg/day of active
ingredient, 7-HF to examine the potential of S. indicus
preparation to treat atherosclerosis. Both hamster and
the LDLr-/- mice showed efficacy in terms of slowing
down atherosclerosis progression without modulating
circulating proatherogenic lipoproteins, suggesting that
the reductions in lesion area was not due to proathero-
genic lipoproteins, but other mechanism(s). This effect
was very different than those observed with fenofibrate,
where reductions in lesion area were associated withhyperlipidemic LDL receptor-deficient mice. Mice were fed Western
gavage for 8 weeks. Mice were fed WD during treatment period. At
urane anesthesia, sacrificed by carbon dioxide asphyxiation, and aorta
Fig. 14 Effect of S. indicus extract on plasma MCP1 and IL-6 in
diet-induced hyperlipidemic LDL receptor-deficient mice. MCP1
and IL-6 measurements were made in the blood samples collected
at the time of terminal bleeding prior to removal of the aorta. Panel a,
Plasma MCP1; and Panel b, Plasma IL-6
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as well as in LDLr-/- mice [30]. Reductions in IL-6, TNF-α,
and MCP-1 do suggest that S. indicus preparation de-
creased aortic lipid deposition by reducing circulating
pro-inflammatory cytokines. These data are consist-
ent with in vitro cell-based findings that showed NF-
kB-mediated down-regulation of pro-inflammatoryFig. 15 Effect of S. indicus extract on aortic MCP1 and TNF-α mRNA in die
animals from each group were not subjected to OilRed O staining. These
and TNF-α mRNAcytokines and adhesion molecules. Natural products
that inhibits NF-kB pathway lower cell adhesion
molecules and pro-inflammatory cytokines, leading
to reduced atherosclerotic burden [56–58] without
changes in circulating lipoprotein levels.
We hypothesized that anti-inflammaory agents showing
efficacy in inflammatory diseases like psoriasis, colitis and
rheumatoid arthritis will inhibit atherosclerosis progres-
sion. Indeed, individuals with psoriasis [18, 20, 59–62],
inflammatory bowel disease [63], and rheumatoid arthritis
[22, 25, 64–67] have greater risks of developing coronary
artery disease. These findings together with chronic
inflammation in atherosclerosis [5, 68] and end stage
kidney disease in diabetics [69] have led to increasing
efforts to discover and develop anti-inflammatory agents
to treat coronary artery disease [70]. NFkB inhibitors
are among anti-inflammatory agents showing anti-
atherosclerotic activities [57, 58, 71]. High-density
lipoproteins shown to regress atherosclerosis is believed
to have an aniinflammatory component [72], in addition
to promoting reverse cholesterol transport [73]. The anti-
atherosclerotic activities of many of the natural products
like alicin [74], catechins [75], abscisic acid [76], marine-
derived wax esters [77], dried plums [78], and a number of
plant-derived flavonoids [79], are attributed to their anti-
inflammatory activities. The anti-atherosclerosis efficacy
of S. indicus preparation in the present study is not
surprising, as a number of anti-inflammatory agents
possess anti-atherosclerosis activities via NF-kB mediated
pathways [57, 58, 71]. Sesquiterpene lactones have been
shown in apoE-/- mice and guinea pigs to have anti-
atherosclerosis efficacy via their anti-inflammatory
activities [80, 81]. Here we showed that S. indicus
preparation with major ingredient 7-HF, a sesquiter-
pene lactone, inhibited atherosclerosis progression int-induced hyperlipidemic LDL receptor-deficient mice. Aortae from 3
aortae were used to prepare total RNA for the quantitation of MCP1
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out and hamsters.
In summary, we showed that the main component of
S. indicus preparation, 7-HF, is an anti-inflammatory
agent that works through NF-kB-mediated pathway, and
inhibits atherosclerosis progression. These findings offer
promise for further clinical benefits to patients with
inflammatory and cardiovascular diseases.
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